Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

The FDA’s proposed PDUFA VIII framework could move manufacturing readiness discussions much earlier in the drug approval process. The plan introduces new CMC facility interactions before submission, stronger communication during inspections and additional engagement after inspection findings. For pharmaceutical sponsors,
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has highlighted a Class 2 recall of one batch of Fingolimod Zentiva 0.5 mg Capsules after shelf-life testing identified a potential risk of metal-particle contamination. Zentiva UK Pharma Limited is recalling
Vitruvias Therapeutics is voluntarily recalling one nationwide lot of Thyroid Tablets, USP 30 mg after testing confirmed potential superpotency. The affected lot 504950 was distributed across the United States between January 31 and September 30, 2025. FDA published the company
The FDA has placed Regenxbio’s experimental Hunter syndrome gene therapy RGX-121 on clinical hold after spinal scans identified abnormalities in five study participants. The patients received the treatment about three to six years ago and remain asymptomatic. However, the regulatory
Karnataka authorities are investigating an alleged interstate drug network after officials seized medicines, expired stock, counterfeit labels, packaging materials and an injection-filling unit worth about ₹4.91 crore from an unlicensed facility near Bidadi. The recovered stock included products labelled as
India’s Central Drugs Standard Control Organisation (CDSCO) has flagged 40 batches of medicines and healthcare products as Not of Standard Quality (NSQ) in its July 2026 surveillance results. The samples failed pharmacopoeial or manufacturer specifications across tests including sterility and
Scholar Rock has withdrawn its European application for apitegromab, its experimental spinal muscular atrophy treatment, and plans to resubmit using a different manufacturing site. The decision follows manufacturing compliance, fill-finish facility, and regulatory path issues at the Bloomington, Indiana site
The U.S. Food and Drug Administration completed an unannounced inspection of Caplin Steriles’ injectable and ophthalmic manufacturing facility in Gummidipoondi, Tamil Nadu, on August 21, 2026. The inspection ended with a Form 483 containing 10 observations. Caplin Point Laboratories said
NATCO Pharma’s finished dosage formulations facility in Parawada, Visakhapatnam, received a U.S. FDA Form 483 with four observations after an inspection conducted from August 17 to 21, 2026. NATCO described the observations as procedural and said it expects to address
Tyra Biosciences is approaching a key test of its “dabogratinib 3x3” strategy as the Carlsbad, California biotech prepares to report initial Phase 2 data from SURF302 in September 2026. The company is developing the same oral FGFR3-selective inhibitor across two